Clinical use of rifampicin during routine reporting of rifampicin susceptibilities: a lesson in selective reporting of antimicrobial susceptibility data
| Autor: | B L Wasilauskas, R M Morrell, C H Steffee |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Antimicrobial susceptibility Microbial Sensitivity Tests Staff education Gram-Positive Bacteria Internal medicine Chart review polycyclic compounds medicine Humans Pharmacology (medical) Antibacterial agent Pharmacology business.industry bacterial infections and mycoses Antimicrobial Anti-Bacterial Agents Surgery Clinical trial Clinical microbiology Infectious Diseases Rifampin business Rifampicin medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 40:595-598 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/40.4.595 |
| Popis: | Increased use of rifampicin for in-patients was noted after the laboratory began reporting rifampicin susceptibilities routinely for all Gram-positive bacterial isolates. The appropriateness of rifampicin use was evaluated by chart review for in-patients administered rifampicin during two time periods, before and during routine rifampicin susceptibility reporting, respectively. While rifampicin susceptibility was reported routinely, four patients were subjected to potentially harmful misuse of rifampicin. These findings reconfirm the necessity of interdepartmental consultation and extensive staff education whenever a modification of antimicrobial susceptibility profile reporting is contemplated. Furthermore, they underscore the role of the clinical microbiology laboratory in guiding antimicrobial therapy through limited reporting of susceptibility data. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|